Pharmacokinetics and clinical significance of drugs for improving nonalcoholic fatty liver disease

Shen MA; Yushuo Liu; Ling Gao; Shen MA; Yushuo Liu; Ling Gao; Shen MA; Yushuo Liu; Ling Gao; Shen MA; Yushuo Liu; Ling Gao; Hui Tang; Wenbin Chen; Ling Gao

Return

Pharmacokinetics and clinical significance of drugs for improving nonalcoholic fatty liver disease

Author: Shen MA ¹ ; Yushuo LIU ¹ ; Ling GAO ¹ ; Shen MA ² ; Yushuo LIU ² ; Ling GAO ² ; Shen MA ³ ; Yushuo LIU ³ ; Ling GAO ³ ; Shen MA ⁴ ; Yushuo LIU ⁴ ; Ling GAO ⁴ ; Hui TANG ⁵ ; Wenbin CHEN ⁶ ; Ling GAO ⁶
Author Information

1. Department of Endocrinology, Shandong Provincial Hospital Affiliated to Shandong First Medical University
2. Shandong Provincial Key Laboratory of Endocrinology and Lipid Metabolism
3. Shandong Clinical Research Center of Diabetes and Metabolic Diseases
4. Shandong Prevention and Control Engineering Laboratory of Endocrine and Metabolic Diseases
5. Stem Cell Clinical Research Center, Shandong Provincial Hospital affiliated to Shandong First Medical University
6. Scientific Center, Shandong Provincial Hospital affiliated to Shandong First Medical University
Publication Type:Journal Article
Keywords: clinical significance; drug; nonalcoholic fatty liver disease; pharmacokinetics
From: Chinese Journal of Clinical Pharmacology and Therapeutics 2022;27(8):908-918
CountryChina
Language:Chinese
Abstract: Nonalcoholic fatty liver disease (NAFLD) is a common chronic liver disease in China. There is no specific drug approved for marketing at home and abroad. At present, some adjuvant drugs are mainly used to improve the progress of the disease. Being familiar with and mastering the pharmacokinetic characteristics is very important for the selection and use of drugs. According to the characteristics of drug absorption, distribution, metabolism and excretion, reasonable drugs are selected to improve the therapeutic effect and reduce adverse reactions. Therefore, this paper reviews the pharmacokinetics and clinical significance of drugs commonly used to improve nonalcoholic fatty liver disease in hope of providing basis for clinical medication.